<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Quinine: malaria; Malarone: malaria treatment; Riamet; Mefloquine: malaria: treatment; Doxycycline: malaria: treatment; Clindamycin: malaria treatment; Sulfadoxine, pyrimethamine with; Pyrimethamine: malaria: sulfadoxine with; Malarone: malaria treatment; Atovaquone: malaria; Proguanil: atovaquone with; Lumefantrine; Quinine: malaria; Artesunate; Clindamycin: malaria treatment; Clindamycin: malaria treatment; Artesunate" /><meta name="IX" content="Quinine: malaria; Malarone: malaria treatment; Riamet; Mefloquine: malaria: treatment; Doxycycline: malaria: treatment; Clindamycin: malaria treatment; Sulfadoxine, pyrimethamine with; Pyrimethamine: malaria: sulfadoxine with; Malarone: malaria treatment; Atovaquone: malaria; Proguanil: atovaquone with; Lumefantrine; Quinine: malaria; Artesunate; Clindamycin: malaria treatment; Clindamycin: malaria treatment; Artesunate" /><title>Falciparum malaria (treatment): British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="16013.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="16013.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=16013.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2071.htm">5 Infections</a> &gt; <a href="4012.htm">5.4 Antiprotozoal drugs</a> &gt; <a href="4013.htm">5.4.1 Antimalarials</a> &gt; <a href="16012.htm">Treatment of malaria</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="16012.htm" title="Previous: Treatment of malaria">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="16014.htm" title="Next: Benign malarias (treatment)">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_16013">Falciparum malaria (treatment)</h1><?highlighter on?><div id="pC" class="jN"><div><p>Falciparum malaria (malignant malaria) is
caused by <span class="cAC">Plasmodium falciparum</span>. In most parts
of the world <span class="cAC">P. falciparum</span> is now resistant to <span>chloroquine</span> which should not therefore be given for treatment.</p><p><b><span>Quinine</span></b>, <b><span class="cZ">Malarone</span></b>® (proguanil with <span>atovaquone</span>), or <b><span class="cZ">Riamet</span></b>® (artemether with lumefantrine)
can be given <i>by mouth</i> if the patient can swallow
and retain tablets and there are no serious manifestations (e.g. impaired
consciousness); <span>quinine</span> should be given <i>by intravenous infusion</i> (see below) if the patient is seriously
ill or unable to take tablets. <span>Mefloquine</span> is now
rarely used for treatment because of concerns about resistance.</p><ul class="cBD"><li><p class="cQ"><i>Oral</i>. The adult dosage regimen for <b><span>quinine</span></b> <i>by mouth</i> is:<br />600 mg (of <span>quinine</span> salt<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113032">(1)</a></sup>) every 8 hours
for 5–7 days <i>together with or followed by</i><br /><i>either</i> <b><span>doxycycline</span></b> 200 mg once daily for 7 days<br /><i>or</i> <b>clindamycin</b> 450 mg every 8 hours for 7 days [unlicensed indication].<br />If the parasite is likely to be sensitive, <b>pyrimethamine</b> 75 mg
with <b>sulfadoxine</b> 1.5 g as a single dose [unlicensed]
may be given (instead of either clindamycin or doxycycline) together
with, or after, a course of quinine.</p></li></ul><p>Alternatively, <b><span class="cZ">Malarone</span></b>®
or <b><span class="cZ">Riamet</span></b>® may be given instead
of <span>quinine</span>. It is not necessary to give <span>doxycycline</span>, <span>clindamycin</span> or pyrimethamine
with sulfadoxine after <span class="cZ">Malarone</span>® or <span class="cZ">Riamet</span>® treatment.</p><ul class="cBD"><li><p class="cQ">The adult dose of <b><span class="cZ">Malarone</span></b>® <i>by mouth</i> is:<br />4 (‘standard’) tablets once daily for 3 days.</p></li></ul><ul class="cBD"><li><p class="cQ">The dose of <b><span class="cZ">Riamet</span></b>® <i>by mouth</i> for adult with body-weight over 35 kg is:<br />4 tablets initially,
followed by 5 further doses of 4 tablets each given at 8, 24, 36,
48, and 60 hours (total 24 tablets over 60 hours).</p></li></ul><ul class="cBD"><li><p class="cQ"><i>Parenteral</i>. If the patient is seriously
ill or unable to take tablets, or if more than 2 % of red blood cell
are parasitized, <b><span>quinine</span></b> should be given <i>by intravenous infusion</i> [unlicensed]. The adult dosage regimen
for <span>quinine</span> <i>by infusion</i> is:<br />loading dose<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113033">(2)</a></sup> of 20 mg/kg<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113035">(3)</a></sup> (up to maximum
1.4 g) of <span>quinine</span> salt<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113032">(1)</a></sup> infused over
4 hours <i>then 8 hours after the start of the loading dose,</i> maintenance dose of 10 mg/kg<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113037">(4)</a></sup> (up to maximum
700 mg) of <span>quinine</span> salt<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113032">(1)</a></sup> infused over
4 hours every 8 hours (until patient can swallow tablets to complete
the 7-day course <i>together with or followed by either</i> <span>doxycycline</span> or <span>clindamycin</span> as above).</p><p class="cQ">Specialist advice should be sought in difficult cases (e.g.
very high parasite count, deterioration on optimal doses of quinine,
infection acquired in quinine-resistant areas of south east Asia)
because intravenous <b><span>artesunate</span></b> may be available for
‘named-patient’ use.</p></li></ul><div class="cAZ"><h2>Children</h2><ul class="cBD"><li><p class="cQ"><i>Oral.</i> <b><span>Quinine</span></b> is well tolerated by children although the salts are bitter.
The dosage regimen for <span>quinine</span> <i>by mouth</i> for children is:</p><p class="cQ">10 mg/kg (of <span>quinine</span> salt<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113032">(1)</a></sup>; max. 600 mg)
every 8 hours for 7 days <i>together with or followed by</i><br /><span><b>Clindamycin</b></span> 7–13 mg/kg (max.
450 mg) every 8 hours for 7 days [unlicensed indication]<br /><i>or</i> in children over 12 years, <b>doxycycline</b> 200 mg once daily for 7 days</p><p class="cQ"><i>or</i> if the parasite is likely to be sensitive, <b>pyrimethamine</b> with <b>sulfadoxine</b> as a single
dose [unlicensed]: up to 4 years and body-weight over 5 kg, pyrimethamine
12.5 mg with sulfadoxine 250 mg; 5–6 years, pyrimethamine 25 mg with
sulfadoxine 500 mg; 7–9 years, pyrimethamine 37.5 mg with sulfadoxine
750 mg; 10–14 years, pyrimethamine 50 mg with sulfadoxine 1 g; 14–18
years, pyrimethamine 75 mg with sulfadoxine 1.5 g</p></li></ul> <p class="cAX">Alternatively, <b><span class="cZ">Malarone</span></b>®
or <b><span class="cZ">Riamet</span></b>® may be given instead
of <span>quinine</span>; it is not necessary to give <span>clindamycin</span>, <span>doxycycline</span>, or pyrimethamine
with sulfadoxine after <span class="cZ">Malarone</span>® or <span class="cZ">Riamet</span>® treatment. The dose regimen for <span class="cZ">Malarone</span>® <i>by mouth</i> for children over 40 kg is the same as for adults
(see above); the dose regimen for <span class="cZ">Malarone</span>® for
smaller children is reduced as follows:</p><ul class="cBD"><li><p class="cQ">body-weight 5–9 kg, 2 ‘paediatric’ tablets once daily
for 3 days; body-weight 9–11 kg, 3 ‘paediatric’ tablets once daily
for 3 days; body-weight 11–21 kg, 1 ‘standard’ tablet once daily for
3 days; body-weight 21–31 kg, 2 ‘standard’ tablets once daily for
3 days; body-weight 31–40 kg, 3 ‘standard’ tablets once daily for
3 days.</p></li></ul><p>The dose regimen of <span class="cZ">Riamet</span>® <i>by mouth</i> for children over 12 years and body-weight over 35 kg is the same
as for adults (see above). The dose regimen for <span class="cZ">Riamet</span>® for children under 12 years is as follows:</p><ul class="cBD"><li><p class="cQ">body-weight 5–15 kg 1 tablet initially, followed by 5
further doses of 1 tablet each given at 8, 24, 36, 48, and 60 hours
(total 6 tablets over 60 hours); body-weight 15–25 kg 2 tablets initially,
followed by 5 further doses of 2 tablets each given at 8, 24, 36,
48, and 60 hours (total 12 tablets over 60 hours); body-weight 25–35 kg
3 tablets initially, followed by 5 further doses of 3 tablets each
given at 8, 24, 36, 48, and 60 hours (total 18 tablets over 60 hours)</p></li></ul><p><i>Parenteral</i>. The dose regimen for <span>quinine</span> <i>by intravenous infusion</i> for children is calculated
on a mg/kg basis as for adults (see above). </p></div><div id="_120613"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Falciparum malaria is particularly dangerous
in pregnancy, especially in the last trimester. The adult treatment
doses of oral and intravenous <span>quinine</span> given above
(including the loading dose) can safely be given to pregnant women. Clindamycin
450 mg every 8 hours for 7 days [unlicensed indication] should be
given with or after quinine. <span>Doxycycline</span> should be avoided in pregnancy (affects teeth and skeletal development); pyrimethamine with sulfadoxine, <span class="cZ">Malarone</span>®, and <span class="cZ">Riamet</span>® are also best avoided until more information is
available. Specialist advice should be sought in difficult cases (e.g. very
high parasite count, deterioration on optimal doses of quinine, infection
acquired in quinine-resistant areas of south east Asia) because intravenous <span>artesunate</span> may be available for ‘named patient’ use.</p></div></div></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="16012.htm">Previous: Treatment of malaria</a> | <a class="top" href="16013.htm#">Top</a> | <a accesskey="]" href="16014.htm">Next: Benign malarias (treatment)</a> ►</div><div class="cF"><div class="footnote" id="footnote113032"><sup>(1)</sup>Valid for <span>quinine</span> hydrochloride, dihydrochloride,
and sulphate; not valid for <span>quinine</span> bisulphate
which contains a correspondingly smaller amount of <span>quinine</span>.</div><div class="footnote" id="footnote113033"><sup>(2)</sup>In intensive care units the loading dose can alternatively be
given as <span>quinine</span> salt<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113032">(1)</a></sup> 7 mg/kg infused over
30 minutes followed immediately by 10 mg/kg over 4 hours then (after
8 hours) maintenance dose as described.</div><div class="footnote" id="footnote113035"><sup>(3)</sup><b>Important:</b> the loading dose of 20 mg/kg should <b>not</b> be used if the patient has received <span>quinine</span> or <span>mefloquine</span> during the previous 12 hours.</div><div class="footnote" id="footnote113037"><sup>(4)</sup>Maintenance dose should be reduced to 5–7 mg/kg of quinine salt<sup class="footnote"><a title="Go to footnote" href="16013.htm#footnote113032">(1)</a></sup> in patients with
severe renal impairment, severe hepatic impairment, or if parenteral
treatment is required for more than 48 hours.</div></div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>